• COVID-19
  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Cognoa Launches Pivotal Study of Diagnostic Aid for Autism

by Fred Pennic 10/25/2019 Leave a Comment

Cognoa Awarded FDA Breakthrough Designations for Diagnostic and Digital Therapeutic Devices for Autism

– Cognoa launches a pivotal study to demonstrate the effectiveness of its diagnostic aid for autism spectrum disorder (ASD).

– The results of this pivotal study will be the basis for the submission to the FDA in 2020.  

– The Cognoa digital diagnostic aid has the potential to become the first cleared medical device to help diagnose autism intended to be used by pediatricians and primary care physicians.

Cognoa, a Palo Alto, CA-based pediatric behavioral health company developing digital medicines, announced the launch of a pivotal study of its digital diagnostic aid for autism. The results of this pivotal study will be the basis for the submission to FDA next year.

Study of Diagnostic Aid for Autism

Cognoa is developing AI-powered digital therapeutics and medicines to advance the standard of care in pediatric behavioral health and improve lifelong outcomes for children. The study is intended to enable pediatricians and physicians in primary care settings to make an autism diagnosis in children as young as 18 months, so that children can receive earlier treatment.

Currently, children are diagnosed for autism by a specialist at an average age of 4 years 4 months, which is after the primary window of brain development when interventions can have the greatest impact. The Cognoa digital diagnostic aid has the potential to become the first cleared medical device to help diagnose autism intended to be used by pediatricians and primary care physicians.

Cognoa is the only digital therapeutics company with two Breakthrough device designations from the FDA for its digital diagnostic aid and a digital therapeutic for autism. The study launch comes soon after the announcement that Cognoa is well underway with plans for commercialization in 2020. Last month, Cognoa announced a partnership with EVERSANA that will enable Cognoa’s digital therapeutics and medicines to be prescribed, dispensed and reimbursed through the existing healthcare infrastructure utilized by medical devices and pharma.

Recent Published Research Studies

Recent published studies reinforce the current crisis in access to timely autism diagnosis and care. In September, a study published in Pediatrics found that the most commonly used screener by pediatricians, the M-CHAT, was less effective in identifying autism than previously reported. Another study found that more than two-thirds of children flagged for autism were not referred to a specialist for treatment. In published studies, prior versions of Cognoa’s algorithm have been clinically validated to screen for autism as early as 18 months of age. Results demonstrate continuous improvements and higher accuracy compared to other behavioral health screening tools including the Revised M-CHAT.

Why It Matters

“Cognoa believes digital therapeutics can fundamentally improve the standard of care for pediatric behavioral health. Our breakthrough products will empower both parents and their trusted family physicians so that every child can receive an earlier diagnosis and treatment when there is the greatest ability to impact the child’s development and improve lifelong outcomes,” said Brent Vaughan, CEO of Cognoa. “Building upon Cognoa’s previous successful clinical studies, this pivotal study is an important milestone for our company. In tandem, we have established our commercial model with our partner, EVERSANA, that will enable access to our digital therapeutics by physicians through existing prescription, distribution and reimbursement infrastructures for utmost efficiency.”

RELATED:   FCC Unveils 14 Initial Projects Selected for $100M Connected Care Pilot Program

Tagged With: AI, Artificial Intelligence, Autism, Behavioral Health, Cognoa, Digital Therapeutics, Family Physicians, FDA, Medical Device, Medical Devices, model, Pharma, physicians, Primary Care

[ultimatesocial networks="facebook,twitter,google,linkedin,mail" url="" custom_class="us-posts-bottom" align="left" count="false"]

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

« Google and care.ai Launches Autonomous Monitoring for Hospitals
Analysis: Why EMRs Will Not Replace Enterprise Imaging IT »

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Recent Articles

  • To Beat COVID-19, We Need A Modern Approach to Public Health Data

    To Beat COVID-19, We Need A Modern Approach to Public Health Data

    ... more
  • HealthStream Acquires Policy Management System ComplyALIGN for $2M

    HealthStream Acquires Policy Management System ComplyALIGN for $2M

    ... more
  • Technologies That Are Transforming the Nursing Profession

    4 Technologies That Are Transforming the Nursing Profession

    ... more
  • mPulse Mobile Acquires Digital Health Engagement Company Big Know

    mPulse Mobile Acquires Digital Health Engagement Company The Big Know

    ... more

Most Read

  • CVS Health Launches Senior Medical Alert System, Symphony CVS Health Launches Senior Medical Alert System, Symphony
  • Philips Acquires Medical Device Integration Platform Capsule for $635M Philips Acquires Medical Device Integration Platform Capsule for $635M
  • 30 Executives Share Top Healthcare Predictions & Trends to Watch in 2021 30 Executives Share Top Healthcare Predictions & Trends to Watch in 2021
  • Job Titles for Healthcare Executives The Top 9 Most In-Demand Medical Jobs
  • 16 COVID-19 Predictions and Trends for 2021 Executive Roundup 12-Available-COVID-19-Vaccine-Management-Solutions-to-Know-In-Depth-1 20 Recently Launched COVID-19 Vaccine Management Solutions to Know
  • DPHO, UnitedHealthcare Launch Accountable Care Program UnitedHealth Rolls Out Employer Virtual Primary Care Plan
  • 3 Steps to Maintain Telehealth’s Momentum Post-Pandemic 3 Steps to Maintain Telehealth’s Momentum Post-Pandemic
  • FCC COVID-19 Telehealth Program Providers FCC Unveils 14 Initial Projects Selected for $100M Connected Care Pilot Program
  • 20 COVID-19 Predictions and Trends for 2021 - Executive Roundup 20 COVID-19 Predictions and Trends for 2021 – Executive Roundup
  • Fundamental Surgery Becomes First VR Surgical Training Simulation to Gain CPD Accreditation 18 Healthcare Augmented Reality and Virtual Reality Companies to Watch

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2020 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2021. HIT Consultant Media. All Rights Reserved. Privacy Policy |